GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.

Abstract

Hypermethylation of GPX3 (glutathione peroxidase 3) promoter has been identified in various solid tumors. However, the pattern of GPX3 promoter methylation in acute myeloid leukemia (AML) remains poorly known. The current study was intended to investigate the clinical significance of GPX3 promoter methylation in de novo AML patients and further determine its role in regulating GPX3 expression. GPX3 promoter methylation status in 181 de novo AML patients and 44 normal controls was detected by real-time quantitative methylation-specific PCR and bisulfite sequencing PCR. Real-time quantitative PCR was carried out to assess GPX3 expression. GPX3 promoter was significantly methylated in 181 AML patients compared with normal controls (P=0.022). The patients with GPX3 methylation presented significantly older age than those with GPX3 unmethylation (P=0.011). GPX3 methylated patients had significantly lower frequency of C/EBPA mutation and higher incidence of FLT3-ITD mutation (P=0.037 and 0.030). The non-M3 patients with GPX3 methylation had significantly lower overall survival than thoes with GPX3 unmethylation (P=0.036). No significant correlation was observed between GPX3 expression and its promoter methylation (R=0.110, P=0.284). However, GPX3 mRNA level was significantly increased after 5-aza-2'-deoxycytidine treatment in leukemic cell line THP1. GPX3 methylation predicts adverse clinical outcome in non-M3 AML patients. Moreover, GPX3 expression is regulated by its promoter methylation in leukemic cell line THP1.

• Authors: Jing-Dong Zhou, Dong-Ming Yao, Ying-Ying Zhang, Ji-Chun Ma, Xiang-Mei Wen, Jing Yang, Hong Guo, Qin Chen, Jiang Lin, Jun Qian
• Journal: American journal of cancer research (Am J Cancer Res) Vol. 5 Issue 5 Pg. 1786-94 ( 2015) ISSN: 2156-6976 [Print] United States
• PMID: 26175946 (Publication Type: Journal Article)